Enarodustat

Clinical data
Trade names	Enaroy
Other names	JTZ-951
Legal status
Legal status	Rx-only (Japan)
Identifiers
IUPAC name 2-{[7-Hydroxy-5-(2-phenylethyl)-[1,2,4]triazolo[1,5-a]pyridin-8-yl]formamido}acetic acid
CAS Number	1262132-81-9
PubChem CID	50899324
DrugBank	14985
ChemSpider	64835234
UNII	JSK7TUA223
KEGG	D11523
ChEMBL	ChEMBL4297619
Chemical and physical data
Formula	C17H16N4O4
Molar mass	340.339 g·mol−1
3D model (JSmol)	Interactive image
SMILES C1=CC=C(C=C1)CCC2=CC(=O)C(=C3N2NC=N3)C(=O)NCC(=O)O
InChI InChI=1S/C17H16N4O4/c22-13-8-12(7-6-11-4-2-1-3-5-11)21-16(19-10-20-21)15(13)17(25)18-9-14(23)24/h1-5,8,10H,6-7,9H2,(H,18,25)(H,19,20)(H,23,24) Key:FJYRBJKWDXVHHO-UHFFFAOYSA-N

Enarodustat (development code JTZ-951; brand name Enaroy) is a drug used for the treatment of anemia, especially when associated with chronic kidney disease (CKD). Enarodustat functions as a inhibitor of hypoxia inducible factor-proly hydroxylase (HIF-PH).^[1]

The drug was approved in September 2020 in Japan for anemia associated with CKD^[2] and is currently in clinical development in the United States and South Korea.^[3] The drug is being developed by Japan Tobacco and JW Pharmaceutical.^[4]